Rhumbline Advisers Sells 2,951 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Rhumbline Advisers lessened its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 0.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 354,900 shares of the medical device company’s stock after selling 2,951 shares during the period. Rhumbline Advisers’ holdings in Cooper Companies were worth $32,626,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ashton Thomas Securities LLC acquired a new position in Cooper Companies during the 3rd quarter worth $25,000. Byrne Asset Management LLC acquired a new position in shares of Cooper Companies during the fourth quarter valued at $33,000. Covestor Ltd lifted its stake in shares of Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 200 shares during the period. Brown Brothers Harriman & Co. boosted its holdings in Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 275 shares during the last quarter. Finally, West Financial Advisors LLC acquired a new stake in Cooper Companies in the fourth quarter worth about $49,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Trading Down 0.9 %

COO opened at $87.29 on Wednesday. The stock has a market capitalization of $17.42 billion, a P/E ratio of 44.76, a P/E/G ratio of 2.41 and a beta of 1.00. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 12 month low of $84.76 and a 12 month high of $112.38. The firm’s fifty day simple moving average is $93.48 and its 200 day simple moving average is $99.74.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the prior year, the firm earned $0.87 earnings per share. Cooper Companies’s revenue for the quarter was up 9.8% compared to the same quarter last year. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on COO shares. Wells Fargo & Company raised their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Citigroup reduced their price objective on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Morgan Stanley dropped their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Friday, December 6th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.